Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 35 of 47 for:    "Acute Lymphoblastic Leukemia, Childhood" | "Pegaspargase"

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005585
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : June 10, 2013
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 2007
Study Completion Date : No date given
Borowitz MJ, Devidas M, Hunger SP, et al.: Prognostic signficance of end consolidation minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG). [Abstract] J Clin Oncol 26 (Suppl 15): A-10000, 2008.
Winick N, Martin PL, Devidas M, et al.: Delayed intensification (DI) enhances event-free survival (EFS) of children with B-precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): POG 9904/9905: a Children's Oncology Group study (COG). [Abstract] Blood 110 (11): A-583, 2007.

Publications automatically indexed to this study by Identifier (NCT Number):